A Clinical trial to study the effects and tolerability of Dacne gel containing Clindamycin Phosphate 1% and zinc acetate in patients suffering from acne.

Assessment of Efficacy, Safety and Tolerability of D?acne (Clindamycin Phosphate 1% and zinc acetate) in the treatment of Acne.

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2011/091/000041

Enrollment

125

Registered

2011-01-27

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- mild to moderate inflammatory acne

Interventions

Intervention1: D?acne (Clindamycin Phosphate 1% and zinc acetate) gel: Apply a thin film of D?acne once daily at bed time to the affected area after washing and rinsing the area well and patting the s

Eligibility

Inclusion criteria

Inclusion criteria: ? Subjects with mild to moderate inflammatory acne with comedones, papules or pustules predominate (Grade 1 and grade 2, IADVL acne grading system) affecting face ? Subjects must be 18-40 years of age ? Subjects must provide written informed consent and comply to the protocol

Exclusion criteria

Exclusion criteria: ? Subjects not willing to discontinue all topical treatments for Acne for 2 weeks prior to enrollment in study ? Hypersensitivity to any ingredients of D?acne ? Pregnant and lactating women. ? Subjects taking Concomitant therapy that might interfere with the study results in the investigator?s opinion. ? Subjects with dermatological disorder of face that may interfere with study evaluation.

Design outcomes

Primary

Measure	Time frame
Reduction in the total number of inflammatory lesions includes - comedones - papules - pustules Timepoint: 6 WEEKS	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Amanjit Ahluwalia

amanjita@glenmarkpharma.com40888094

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026